Cutting Edge: Nucleocapsid Vaccine Elicits Spike-Independent SARS-CoV-2 Protective Immunity.
J Immunol
; 207(2): 376-379, 2021 07 15.
Article
em En
| MEDLINE
| ID: mdl-34193597
ABSTRACT
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is responsible for the COVID-19 pandemic. Neutralizing Abs target the receptor binding domain of the spike (S) protein, a focus of successful vaccine efforts. Concerns have arisen that S-specific vaccine immunity may fail to neutralize emerging variants. We show that vaccination with a human adenovirus type 5 vector expressing the SARS-CoV-2 nucleocapsid (N) protein can establish protective immunity, defined by reduced weight loss and viral load, in both Syrian hamsters and K18-hACE2 mice. Challenge of vaccinated mice was associated with rapid N-specific T cell recall responses in the respiratory mucosa. This study supports the rationale for including additional viral Ags in SARS-CoV-2 vaccines, even if they are not a target of neutralizing Abs, to broaden epitope coverage and immune effector mechanisms.
Texto completo:
1
Bases de dados:
MEDLINE
Assunto principal:
Linfócitos T CD8-Positivos
/
Proteínas do Nucleocapsídeo de Coronavírus
/
Vacinas contra COVID-19
/
SARS-CoV-2
/
COVID-19
/
Anticorpos Antivirais
Limite:
Animals
Idioma:
En
Revista:
J Immunol
Ano de publicação:
2021
Tipo de documento:
Article
País de afiliação:
Mongólia